Module 2: Treatment Selection and Sequencing in Late Relapse

Return to Enrollment Page

OVERVIEW

This case will review the journey of a 41 year old male patient with quadruple-refractory multiple myeloma who works with his hematology/oncology specialist to select the next steps in his MM treatment journey.

FACULTY

Shambavi Richard, MD

Director of Myeloma and Lymphoma at Mount Sinai West of the Mount Sinai School of Medicine/Icahn School of Medicine
Associate Professor of Medicine 
Division of Multiple Myeloma 
Mount Sinai Hospital 
New York, NY 

Shambavi Richard, MD, Director of Myeloma and Lymphoma, Mount Sinai West of the Mount Sinai School of Medicine/Icahn School of Medicine, New York, NY, received her MBBS at Stanley Medical College, University of Madras, Chennai,
India; and Internal Medicine Residency at Bronx-Lebanon Hospital/Albert Einstein College of Medicine, Bronx, NY. Dr. Richard has been a practicing hematologist/oncologist with expertise in hematologic malignancies and stem-cell transplants. She has also been a faculty member for several academic institutions as well as principal investigator for many clinical industry-sponsored trials, making valuable contributions in both the academic world and hematology/oncology practice setting.

Brea Lipe, MD

Clinical Director, Multiple Myeloma Program 
Professor, Department of Medicine, Division of Hematology and Oncology 
James P. Wilmot Cancer Institute
University of Rochester Medical Center
Rochester, NY

Brea C. Lipe, MD, is Clinical Director, the Multiple Myeloma Program, and Professor, Department of Medicine, Division of Hematology and Oncology, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY. She earned her BA in Biology and Philosophy from the University of Colorado, Boulder, CO, and MD from Albany Medical College, Albany, NY. Dr. Lipe is focused on the care of patients with multiple myeloma and other plasma cell dyscrasias, bringing her strong clinical research expertise to a complex disease, as can be found in many international publications and presentations.  

LEARNING OBJECTIVES

1.
Recognize the optimal timing to restart therapy in individual patients with MM in early relapse.
2.
Optimize sequencing of therapies for RRMM using clinical data, guidelines, patient preferences and strategies for addressing access barriers.
3.
Discuss the safety and efficacy data for new and emerging therapies in RRMM.